B Cell News and Research

RSS

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

Evaluating next-generation sequencing (NGS) data and associated clinical records of head and neck squamous cell carcinoma (HNSCC) patients from several institutions, made available through The Cancer Genome Atlas (TCGA), showed that combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with the patient's HPV status provides an effective indicator of improved patient outcome, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

Lone star tick bites are likely the cause of severe red meat allergies

Lone star tick bites are likely the cause of thousands of cases of severe red meat allergies that are plaguing patients in Southeastern states including Tennessee, North Carolina and Virginia and spreading up the Eastern Seaboard along with the deer population.

21 Feb 2014

Epidemiological studies demonstrate that diseases of central nervous system protect against cancer

Epidemiological studies demonstrate that diseases of the central nervous system such as Alzheimer, Parkinson and schizophrenia protect against cancer. The most remarkable example is Alzheimer's disease, which can reduce the risk of suffering from cancer by up to 50%.

21 Feb 2014

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

A retrospective analysis of oropharyngeal patients with recurrence of disease after primary therapy in the Radiation Therapy Oncology Group (RTOG) studies 0129 or 0522 found that HPV-positive patients had a higher overall survival (OS) rate than HPV-negative patients (at two years post-treatment, 54.6 percent vs. 27.6 percent, respectively), according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

20 Feb 2014

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Pharmacyclics, Inc. today reported financial results and recent developments for the quarter and year ended December 31, 2013.

20 Feb 2014

Predictors of bone metastasis, skeletal events in lung cancer identified

Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events.

20 Feb 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

Newly developed compound may allow blind see light

Progressive degeneration of photoreceptors-the rods and cones of the eyes-causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to reverse this degeneration, a newly developed compound allows other cells in the eye to act like photoreceptors. As described in a study appearing in the February 19 issue of the Cell Press journal Neuron, the compound may be a potential drug candidate for treating patients suffering from degenerative retinal disorders.

20 Feb 2014

Pediatric Cancer Genome Project identifies genetic alteration in brain tumor ependymoma

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified the most common genetic alteration ever reported in the brain tumor ependymoma and evidence that the alteration drives tumor development. The research appears February 19 as an advanced online publication in the scientific journal Nature.

20 Feb 2014

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.

20 Feb 2014

UPV/EHU researchers develop method for diagnosis, prognosis of cutaneous melanoma

UPV/EHU researchers have developed a method for the diagnosis and prognosis of cutaneous melanoma, the type of skin cancer with the highest mortality rate.This method will help not only in the more effective early detection of this cancer, but also in the development of more personalised treatments.

20 Feb 2014

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Oncologists and cancer patients could improve the results of drug therapies by making real-time decisions about treatment options using an innovation developed in Purdue University's College of Pharmacy.

20 Feb 2014

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

20 Feb 2014

NIH-funded session in Bethesda to heighten awareness of underactive bladder

Underactive bladder, estimated to affect more than 20 percent of the elderly population, is an unrecognized disease that has a major influence on the health and independence of seniors.

20 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Deficiency in SNX27 explains learning impairment in Down's syndrome

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have identified the precise role of the protein, SNX27, in the pathway leading to memory and learning impairment.

20 Feb 2014

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

From PBL Assay Science 20 Feb 2014

New biologic drug to prevent growth of ovarian cancer cells

Researchers at Women & Infants Hospital of Rhode Island have developed a biologic drug that would prevent the production of a protein known to allow ovarian cancer cells to grow aggressively while being resistant to chemotherapy. This would improve treatment and survival rates for some women.

20 Feb 2014

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

Joseph C. Glorioso, III, PhD (University of Pittsburgh School of Medicine, PA) devoted much of his research career to developing herpes viruses as efficient vectors for delivering therapeutic genes into cells.

20 Feb 2014

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

The Cystinosis Research Foundation awarded $2,153,048 in 2013 to researchers investigating better treatments and a cure for cystinosis, a rare metabolic and genetic disease that afflicts about 500 children and young adults in the United States and 2,000 worldwide.

19 Feb 2014

B Cell News and Research

MATH biomarker with HPV status may provide improved outcomes in HNSCC patients

Lone star tick bites are likely the cause of severe red meat allergies

Epidemiological studies demonstrate that diseases of central nervous system protect against cancer

HPV-positive patients with OPSCC show higher overall survival rate than HPV-negative patients

Pharmacyclics total revenue for fourth quarter 2013 increases 113% to $123.6 million

Predictors of bone metastasis, skeletal events in lung cancer identified

Lung cancer patients with Del19 mutation benefit most from afatinib

Newly developed compound may allow blind see light

Pediatric Cancer Genome Project identifies genetic alteration in brain tumor ependymoma

Certain fragments of DNA shed by tumors can be used to non-invasively screen for early-stage cancers

UPV/EHU researchers develop method for diagnosis, prognosis of cutaneous melanoma

Purdue’s new innovation improves drug therapies by making real-time decisions about treatment options

Vaccine-based clinical trial to improve survival outcomes of kidney cancer patients

NIH-funded session in Bethesda to heighten awareness of underactive bladder

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Deficiency in SNX27 explains learning impairment in Down's syndrome

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

New biologic drug to prevent growth of ovarian cancer cells

Researcher receives Pioneer Award for engineering herpes simplex virus gene delivery systems

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Industry focus eBook - Cell and gene therapy (2nd edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News